JP2024516309A5 - - Google Patents
Info
- Publication number
- JP2024516309A5 JP2024516309A5 JP2023568063A JP2023568063A JP2024516309A5 JP 2024516309 A5 JP2024516309 A5 JP 2024516309A5 JP 2023568063 A JP2023568063 A JP 2023568063A JP 2023568063 A JP2023568063 A JP 2023568063A JP 2024516309 A5 JP2024516309 A5 JP 2024516309A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- months
- immunogenic composition
- composition according
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163184727P | 2021-05-05 | 2021-05-05 | |
| US63/184,727 | 2021-05-05 | ||
| US202163193356P | 2021-05-26 | 2021-05-26 | |
| US63/193,356 | 2021-05-26 | ||
| US202163255685P | 2021-10-14 | 2021-10-14 | |
| US63/255,685 | 2021-10-14 | ||
| US202263332537P | 2022-04-19 | 2022-04-19 | |
| US63/332,537 | 2022-04-19 | ||
| PCT/US2022/027465 WO2022235663A1 (en) | 2021-05-05 | 2022-05-03 | Coronavirus and influenza compositions and methods for using them |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516309A JP2024516309A (ja) | 2024-04-12 |
| JP2024516309A5 true JP2024516309A5 (enExample) | 2025-05-15 |
Family
ID=83901839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023568063A Pending JP2024516309A (ja) | 2021-05-05 | 2022-05-03 | コロナウイルス組成物及びインフルエンザ組成物ならびにそれらの使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220354944A1 (enExample) |
| EP (1) | EP4333885A4 (enExample) |
| JP (1) | JP2024516309A (enExample) |
| KR (1) | KR20240024064A (enExample) |
| AU (1) | AU2022270082A1 (enExample) |
| BR (1) | BR112023023035A2 (enExample) |
| CA (1) | CA3217591A1 (enExample) |
| IL (1) | IL308180A (enExample) |
| MX (1) | MX2023013081A (enExample) |
| TW (1) | TW202308685A (enExample) |
| WO (1) | WO2022235663A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| AU2021214064A1 (en) | 2020-01-27 | 2022-08-18 | Novavax, Inc. | Coronavirus vaccine formulations |
| WO2024174012A1 (pt) * | 2023-02-24 | 2024-08-29 | Instituto Butantan | Composição imunogênica, uso da mesma e processo de obtenção de uma composição imunogênica combinada contra covid-19 e influenza sazonal |
| AU2024253607A1 (en) * | 2023-04-03 | 2025-10-16 | Novavax, Inc. | Coronavirus and influenza compositions and methods for using them |
| US20250085282A1 (en) * | 2023-09-11 | 2025-03-13 | Novavax, Inc. | Method for detecting anti-sars-cov-2 spike (s) immunoglobulins |
| US20250144200A1 (en) * | 2023-11-06 | 2025-05-08 | Novavax, Inc. | Intranasal immunogenic compositions |
| EP4670733A1 (en) * | 2024-06-27 | 2025-12-31 | Sanofi | METHODS FOR PREPARING VIRAL PROTEINS AND THEIR USES |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| SE8405493D0 (sv) | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
| US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| US6387373B1 (en) | 1993-01-15 | 2002-05-14 | Novavax, Inc. | Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| US5629021A (en) | 1995-01-31 | 1997-05-13 | Novavax, Inc. | Micellar nanoparticles |
| US6846489B1 (en) | 1995-04-25 | 2005-01-25 | Smithkline Beecham Biologicals S.A. | Vaccines containing a saponin and a sterol |
| SE9600647D0 (sv) | 1996-02-21 | 1996-02-21 | Bror Morein | Ny användning |
| US6231859B1 (en) | 1996-12-02 | 2001-05-15 | Aquila Biopharmaceuticals, Inc. | Saponin adjuvant compositions |
| DE60044236D1 (de) | 1999-02-17 | 2010-06-02 | Csl Ltd | Immunogene komplexe und methoden in bezug auf diese |
| CA2805741C (en) | 2010-07-23 | 2019-08-13 | Karin Bengtsson Loevgren | Composition including an iscom matrix and ectodomains |
| WO2012104820A1 (en) * | 2011-02-04 | 2012-08-09 | Pfizer Inc. | Compositions for canine respiratory disease complex |
| EP3046579A1 (en) * | 2013-09-19 | 2016-07-27 | Novavax, Inc. | Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods |
| CN114617959A (zh) | 2015-09-03 | 2022-06-14 | 诺瓦瓦克斯股份有限公司 | 具有改进的稳定性和免疫原性的疫苗组合物 |
| WO2018081318A1 (en) | 2016-10-25 | 2018-05-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion coronavirus spike proteins and their use |
| CN110418593B (zh) | 2017-10-20 | 2022-04-19 | 科亚列士信荣株式会社 | 半成品卷制造装置 |
| CN120227451A (zh) * | 2018-03-19 | 2025-07-01 | 诺瓦瓦克斯股份有限公司 | 多价流感纳米颗粒疫苗 |
| AU2021214064A1 (en) * | 2020-01-27 | 2022-08-18 | Novavax, Inc. | Coronavirus vaccine formulations |
| US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| US12194089B2 (en) * | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| EP4135762A4 (en) * | 2020-04-14 | 2024-05-15 | The Regents of the University of California | Large sequence pan-coronavirus vaccine compositions |
| GB2596820A (en) * | 2020-07-07 | 2022-01-12 | Spicona Inc | Combination vaccine |
| CN112546211A (zh) | 2020-10-23 | 2021-03-26 | 嘉晨西海(杭州)生物技术有限公司 | 基于mRNA的针对冠状病毒和流感病毒的联合疫苗及其制备方法 |
| CN112480217B (zh) * | 2020-11-30 | 2022-04-08 | 广州阿格纳生物医药制造有限公司 | 基于SARS-CoV-2的S抗原蛋白的疫苗和组合物 |
| CN113185613B (zh) * | 2021-04-13 | 2022-09-13 | 武汉大学 | 新型冠状病毒s蛋白及其亚单位疫苗 |
-
2022
- 2022-05-03 JP JP2023568063A patent/JP2024516309A/ja active Pending
- 2022-05-03 IL IL308180A patent/IL308180A/en unknown
- 2022-05-03 WO PCT/US2022/027465 patent/WO2022235663A1/en not_active Ceased
- 2022-05-03 AU AU2022270082A patent/AU2022270082A1/en active Pending
- 2022-05-03 KR KR1020237041628A patent/KR20240024064A/ko active Pending
- 2022-05-03 CA CA3217591A patent/CA3217591A1/en active Pending
- 2022-05-03 MX MX2023013081A patent/MX2023013081A/es unknown
- 2022-05-03 EP EP22799423.3A patent/EP4333885A4/en active Pending
- 2022-05-03 BR BR112023023035A patent/BR112023023035A2/pt unknown
- 2022-05-04 US US17/736,452 patent/US20220354944A1/en active Pending
- 2022-05-05 TW TW111116974A patent/TW202308685A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023512648A5 (enExample) | ||
| JP2026026092A5 (enExample) | ||
| Chroboczek et al. | Virus-like particles as vaccine. | |
| RU2018111760A (ru) | Вакцинные композиции, характеризующиеся улучшенной стабильностью и иммуногенностью | |
| JP5683811B2 (ja) | キメラインフルエンザウイルス様粒子 | |
| AU2006279323B2 (en) | Influenza recombinant subunit vaccine | |
| KR100871021B1 (ko) | 인플루엔자 백신 조성물 | |
| JP2024511412A5 (enExample) | ||
| US7528223B2 (en) | Antigens encoded by alternative reading frames from pathogenic viruses | |
| JP2000516199A (ja) | ウマの予防用ポリヌクレオチドワクチン製剤 | |
| JP2013542224A5 (enExample) | ||
| CA2383105A1 (en) | Intranasal influenza virus vaccine | |
| IL305911A (en) | Multifunctional nanoparticle vaccines for influenza | |
| JP2014506562A5 (ja) | 治療的免疫応答及び予防的免疫応答の両方を誘発するポリペプチド（複数可）保持ＣｙａＡ及びその使用 | |
| CN113226364A (zh) | 组合物和方法 | |
| EP3474891B1 (en) | Vaccine compositions comprising an attenuated mutant zika virus | |
| JP2024545420A5 (enExample) | ||
| WO2024041612A1 (zh) | 一种正痘病毒属mRNA疫苗及其制备方法和用途 | |
| JP2023134738A (ja) | 呼吸器疾患を治療するための方法および組成物 | |
| US9198965B2 (en) | Peptide adjuvant for influenza vaccination | |
| BRPI0811692A2 (pt) | material com imunogenicidade | |
| Kim et al. | Generation of VHSV replicon particles carrying transmembrane and C-terminal cytoplasmic region-deleted G gene (rVHSV-GΔTM) and comparison of vaccine efficacy with G gene-deleted VHSV (rVHSV-ΔG) | |
| JP4797149B2 (ja) | インフルエンザウイルスに対するベクターワクチン | |
| JP2023519562A5 (enExample) | ||
| US20140199347A1 (en) | Adjuvant compositions with 4-1bbl |